Nucleic acid vaccines have arrived with unprecedented speed and impact. We make them even better.

Introducing Orlance MACH-1®

LOW-DOSE, HIGHLY SCALABLE POWDERED NUCLEIC ACID VACCINES WITHOUT COLD CHAIN REQUIREMENTS.

Orlance, Inc., headquartered in Seattle, WA, is developing its MACH-1® platform to deliver nucleic acid vaccines and related therapies without cold chain restrictions.  Leveraging $9.6M in NIH SBIR funding, Orlance has developed the MACH-1 platform to intradermally deliver stable, powdered vaccines in a needle-free manner that minimizes dose size, eliminates cold chain requirements, and is poised to increase access and compliance.  The company’s executive team comprises significant immunology, vaccinology, biotech development, bioengineering, regulatory and partnering experience and is well poised to bring its preclinical assets to IND and Phase 1 readiness in 2021.

Meet Us At:

Biotech Showcase, January 11-15, 2021

Fierce JPM Week, Jan 11-13, 2021

Our Team

Orlance, inc

Kris Alto

CEO

25 years of bioengineering, innovation development, regulatory and clinical affairs, product launch, VC and executive experience.

Deb Fuller

PhD, CTO

co-inventor of MACH-1 technology, formerly at PowderJect, UW Professor, the lab focuses on NA vaccines for multiple pathogens.

Jim Mullins

PhD

co-founder and SAB member, UW, molecular and computational approaches vaccine design, the originator of conserved element (CE) approach to vaccine development.

Ken Bagley

PhD, Dir. R&D

15 years in NA vaccine field, developed genetic adjuvant platform at Profectus Biosciences, Inc.

Hannah Frizzell

PhD

Bioengineer, Immunology, and nano delivery system experience.

IF YOU’RE A POTENTIAL PARTNER

Series A or government funding for Phase 1/2a Orlance MACH-1® influenza or CoV vaccine

DNA and mRNA vaccine Phase 1 candidates

© 2021 Orlance Inc. | Site by Malolo Design